Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Videos

Christina is the associate editorial director of 

 in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.

She has a BS in public health from Rutgers University. You can connect with Christina on 

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

Ruxolitinib Plus Anemia Supportive Care Maintains Efficacy in Myelofibrosis: Pankit Vachhani, MD 

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Articles

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss in lean muscle.

Weight Loss Drug HU6 Shows Promise in MASH With Muscle-Sparing Benefits

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

A deep learning generative model is capable of autonomously learning about idiopathic pulmonary fibrosis. 

AI Identifies Possible New Therapy for IPF

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

Gastroenterology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

MASH

Hepatology

Allergy

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Rheumatoid Arthritis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Small Cell Lung Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Participating Faculty

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Gene Polymorphism Influences Response to Angiotensin Blockade

New Drug Class Offers Benefits in Heart Failure

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

European Society of Cardiology: Angiotensin II Antagonists:  Why is There So Much Excitement?

What are the Pharmacological Differences Between Angiotensin II Antagonists

Clinical Implications of Differences Between Angiotensin II Antagonists

Exploring the Benefits Beyond Blood Pressure Control

How Far Have We Come in Treating Congestive Heart Failure?

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Angiotensin Receptor Blockers: Cardio-renal Implications in Patients with Congestive Heart Failure

Selected Abstracts

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure

Supplements and Featured Publications

SUPPLEMENT CONTENT

Supplements

Publications

What are the Pharmacological Differences Between Angiotensin II Antagonists

Newsletter